Meningioma

However, NTRK gene aberrations are rare, necessitating FISH or next-generation sequencing confirmation for pan-TRK-positive cases to identify candidates for TRK-targeted therapy. Further studies are needed to clarify the biological role of non-fusion-mediated pan-TRK overexpression in meningioma progression.

Categorical E-cadherin reporting enhances its utility over continuous H-scores alone. Thus, even in the absence of glial tissue in biopsy specimen, these biomarkers may help to suggest invasive nature of tumor in appropriate clinical context.

The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate...We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy...A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma.

To the authors' knowledge, this is the first reported case of a spinal SFT with metastasis to the fourth ventricle and the first epithelioid SFT presenting within the fourth ventricle. Long-term follow-up is recommended due to the risk of local recurrence and metastases. https://thejns.org/doi/10.3171/CASE25414.

Methods We evaluated the effects of the Gal-3 inhibitor TD139 combined with either low-intensity direct current electrostimulation (DCES) on meningioma cells in a human co-culture model, or non-invasive transcranial direct current stimulation (tDCS) in an orthotopic preclinical model...This combination treatment was also associated with a significant decrease in the meningioma-associated marker NDRG4 and the proliferation marker Ki-67. Conclusion The results indicate that combining Gal-3 inhibitors with direct current stimulation has potential as an effective treatment modality for aggressive meningiomas.

In conclusion, this study demonstrates that rs1136410 is significantly associated with brain tumor risk particularly with the glioma and meningioma subtypes underscoring the role of PARP1 in brain tumor genetics and its potential as a therapeutic target.

The top-ranked miRNAs were also analysed and compared with biomarkers previously known from the literature. Seven miRNAs were identified as potential biomarkers, namely the miR-125a-3p, miR-4276, miR-4648, miR-4763-3p, miR-663a, miR-6784-5p and miR-873-3p, and were independently validated on the GSE211692 dataset.

WDRT provides excellent local control and adequate safety profiles in NF2-SWN patients with meningiomatosis. Further prospective studies with a predefined target volume are warranted to validate our findings.

Combined PRRT with 225Ac/177Lu-DOTATATE appears feasible and potentially beneficial option in advanced meningiomas. However, given the small sample size, treatment heterogeneity, and lack of controlled comparison, the findings should be interpreted with caution. Larger prospective studies are warranted.

As a result, genetic knowledge is essential not only for diagnosis but also for appreciating the complexity and heterogeneity of these syndromes in clinical practice. Finally, this discussion includes other TPS that, while not yet classified as distinct entities in the current edition of the WHO Classification of Tumors of the CNS, remain relevant to the field of neuro-oncology.

[This retracts the article DOI: 10.1155/2022/6423237.].

P1, N=24, Not yet recruiting, Capital Medical University